Have a feature idea you'd love to see implemented?
Let us know!
FDMT 4D Molecular Therapeutics Inc
Price (delayed)
$8.21
Market cap
$426.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$251.27M
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector
Highlights
4D Molecular Therapeutics's EPS has increased by 30% YoY and by 6% from the previous quarter
The company's debt fell by 13% YoY and by 3.6% QoQ
The company's equity has surged by 81% YoY but it fell by 2% QoQ
FDMT's quick ratio is up by 24% YoY but it is down by 13% QoQ
The company's net income fell by 5% QoQ
Key stats
What are the main financial stats of FDMT
Market
Valuations
Earnings
Shares outstanding
51.97M
Market cap
$426.67M
Enterprise value
$251.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
22.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.43
Revenue
$20.22M
EBIT
-$109.89M
EBITDA
-$103.77M
Free cash flow
-$87.17M
Per share
Balance sheet
Liquidity
EPS
-$2.3
Free cash flow per share
-$1.58
Book value per share
$11.38
Revenue per share
$0.37
TBVPS
$11.22
Total assets
$620.12M
Total liabilities
$31.78M
Debt
$13.66M
Equity
$588.34M
Working capital
$533.23M
Debt to equity
0.02
Current ratio
28.48
Quick ratio
27.93
Net debt/EBITDA
1.69
Margins
Efficiency
Dividend
EBITDA margin
-513.2%
Gross margin
100%
Net margin
-543.5%
Operating margin
-649%
Return on assets
-22.5%
Return on equity
-24.1%
Return on invested capital
-46.4%
Return on capital employed
-18.3%
Return on sales
-543.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FDMT stock price
How has the 4D Molecular Therapeutics stock price performed over time
Intraday
-3.53%
1 week
-2.84%
1 month
-28.55%
1 year
-21.96%
YTD
-59.48%
QTD
-24.05%
Financial performance
How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$20.22M
Gross profit
$20.22M
Operating income
-$131.22M
Net income
-$109.89M
Gross margin
100%
Net margin
-543.5%
The company's net margin has surged by 89% YoY but it fell by 6% QoQ
The operating margin has soared by 87% YoY but it has contracted by 10% from the previous quarter
The operating income is down by 12% YoY and by 9% QoQ
The company's net income fell by 5% QoQ
Growth
What is 4D Molecular Therapeutics's growth rate over time
Valuation
What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
0.72
P/S
22.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.43
4D Molecular Therapeutics's EPS has increased by 30% YoY and by 6% from the previous quarter
The company's equity has surged by 81% YoY but it fell by 2% QoQ
The stock's P/B is 67% below its last 4 quarters average of 2.2
The P/S is 54% lower than the last 4 quarters average of 49.2
Efficiency
How efficient is 4D Molecular Therapeutics business performance
4D Molecular Therapeutics's ROS has soared by 89% YoY but it has decreased by 6% from the previous quarter
The return on equity is up by 44% year-on-year and by 10% since the previous quarter
The ROA has grown by 42% YoY and by 9% from the previous quarter
The return on invested capital rose by 30% year-on-year and by 29% since the previous quarter
Dividends
What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FDMT.
Financial health
How did 4D Molecular Therapeutics financials performed over time
4D Molecular Therapeutics's total assets has soared by 76% YoY
FDMT's quick ratio is up by 24% YoY but it is down by 13% QoQ
The company's debt is 98% lower than its equity
The company's equity has surged by 81% YoY but it fell by 2% QoQ
FDMT's debt to equity has dropped by 60% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.